Related Experiment Videos
[The high-dose gamma-globulin therapy for inflammatory demyelinating peripheral neuropathy: evaluations of clinical
H Ishihara1, K Kondou, F Sofue
1Department of neurology, Fujita Health University.
Purpose Of The Study:
To clarify the clinical effects and the influence of high-dose therapy of gamma-globulin for inflammatory demyelinating peripheral neuropathy, we have investigated changes of serum IgG subclass distribution of the patients with these diseases by this therapy.
Subjects And Methods:
gamma-Globulin (20g/day) was intravenously administrated for 5 days in 4 cases of CIDP, 2 cases of Fisher syndrome and 1 case of Guillain-Barré syndrome. The IgG subclass was measured by sandwich ELISA method four times, namely before the treatment, immediately after, and 2 and 4 weeks after the treatment.
Results:
Marked symptomatical improvement was observed in all cases. Serum levels of all IgG subclasses were highest just after the therapy, and all subclasses recovered to the pretherapeutic levels in 4 weeks. Attitude of changes in all IgG subclasses of all cases was fairly similar each other.
Conclusion:
These results suggest that high-dose therapy of gamma-globulin is an effective therapy for inflammatory demyelinating peripheral neuropathy with little influences on IgG production and metabolism of IgG.